This analysis investigated the prognostic value of hospitalisation in chronic thromboembolic pulmonary hypertension (CTEPH) using data from the Czech Republic, wherein pulmonary endarterectomy (PEA) was the only targeted treatment option until 2015. Using a landmark method, this analysis quantified the association between a first CTEPH-related hospitalisation event occurring before 3-, 6-, 9-, and 12-month landmark timepoints and subsequent all-cause mortality in adult CTEPH patients diagnosed between 2003 and 2016 in the Czech Republic. Patients were stratified into operable and inoperable, according to PEA eligibility. CTEPH-related hospitalisations were defined as non-elective. Hospitalisations related to CTEPH diagnosis, PEA, balloon pulmonary angioplasty, or clinical trial participation were excluded. Of 436 patients who survived to ≥3 months post diagnosis, 309 were operable, and 127 were inoperable. Sex- and age-adjusted hazard ratios (HRs) showed CTEPH-related hospitalisation was a statistically significant prognostic indicator of mortality at 3, 9, and 12 months in inoperable patients, with an approximately 2-fold increased risk of death in the hospitalisation group (HRs [95% CI] ranging from 1.98 [1.06-3.70] to 2.17 [1.01-4.63]). There was also a trend of worse survival probabilities in the hospitalisation groups for operable patients, with the difference most pronounced at 3 months, with a 76% increased risk of death (adjusted HR [95% CI] 1.76 [1.15-2.68]). This first analysis on the prognostic value of CTEPH-related hospitalisations demonstrates that a first CTEPH-related hospitalisation is prognostic of mortality in CTEPH, particularly for inoperable patients. These patients may benefit from medical and/or interventional therapy.

2nd Department of Internal Medicine Department of Cardiovascular Medicine 1st Faculty of Medicine Charles University and General University Hospital 128 08 Prague Czech Republic

2nd Department of Surgery Department of Cardiovascular Surgery 1st Faculty of Medicine Charles University and General University Hospital 128 08 Prague Czech Republic

Actelion Pharmaceuticals Ltd A Janssen Pharmaceutical Company of Johnson and Johnson 4123 Allschwil Switzerland

Data Analysis Department Institute of Biostatistics and Analysis Ltd 602 00 Brno Czech Republic

Department of Anesthesiology and Intensive Care 1st Faculty of Medicine Charles University and General University Hospital 128 08 Prague Czech Republic

Department of Radiology 1st Faculty of Medicine Charles University and General University Hospital 128 08 Prague Czech Republic

J Clin Med. 2023 Jun 09;12(12):3939. doi: 10.3390/jcm12123939. PubMed

Zobrazit více v PubMed

Galiè N., Humbert M., Vachiery J.L., Gibbs S., Lang I., Torbicki A., Simonneau G., Peacock A., Vonk Noordegraaf A., Beghetti M., et al. 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT) Eur Respir. J. 2015;46:903–975. doi: 10.1183/13993003.01032-2015. PubMed DOI

Delcroix M., Torbicki A., Gopalan D., Sitbon O., Klok F.A., Lang I., Jenkins D., Kim N.H., Humbert M., Jais X., et al. ERS statement on chronic thromboembolic pulmonary hypertension. Eur. Respir. J. 2020;59:2102006. doi: 10.1183/13993003.02828-2020. PubMed DOI

Leber L., Beaudet A., Muller A. Epidemiology of pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension: Identification of the most accurate estimates from a systematic literature review. Pulm Circ. 2021;11:2045894020977300. doi: 10.1177/2045894020977300. PubMed DOI PMC

Delcroix M., Lang I., Pepke-Zaba J., Jansa P., D’Armini A.M., Snijder R., Bresser P., Torbicki A., Mellemkjaer S., Lewczuk J., et al. Long-term outcome of patients with chronic thromboembolic pulmonary hypertension: Results from an international prospective registry. Circulation. 2016;133:859–871. doi: 10.1161/CIRCULATIONAHA.115.016522. PubMed DOI

Quadery S.R., Swift A.J., Billings C.G., Thompson A.A., Elliot C.A., Hurdman J., Charalampopoulos A., Sabroe I., Armstrong I.J., Hamilton N., et al. The impact of patient choice on survival in chronic thromboembolic pulmonary hypertension. Eur. Respir. J. 2018;52:1800589. doi: 10.1183/13993003.00589-2018. PubMed DOI PMC

Kim N.H., Delcroix M., Jais X., Madani M.M., Matsubara H., Mayer E., Ogo T., Tapson V.F., Ghofrani H.A., Jenkins D.P. Chronic thromboembolic pulmonary hypertension. Eur. Respir. J. 2019;53:1465–1472. doi: 10.1183/13993003.01915-2018. PubMed DOI PMC

Gall H., Hoeper M.M., Richter M.J., Cacheris W., Hinzmann B., Mayer E. An epidemiological analysis of the burden of chronic thromboembolic pulmonary hypertension in the USA, Europe and Japan. Eur. Respir. Rev. 2017;26:160121. doi: 10.1183/16000617.0121-2016. PubMed DOI PMC

Humbert M., Kovacs G., Hoeper M.M., Badagliacca R., Berger R.M.F., Brida M., Carlsen J., Coats A.J.S., Escribano-Subias P., Ferrari P., et al. 2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: Developed by the task force for the diagnosis and treatment of pulmonary hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS). Endorsed by the International Society for Heart and Lung Transplantation (ISHLT) and the European Reference Network on rare respiratory diseases (ERN-LUNG) Eur. Heart J. 2022;43:ehac237. doi: 10.1093/eurheartj/ehac237. PubMed DOI

McLaughlin V.V., Hoeper M.M., Channick R.N., Chin K.M., Delcroix M., Gaine S., Ghofrani H.A., Jansa P., Lang I.M., Mehta S., et al. Pulmonary arterial hypertension-related morbidity is prognostic for mortality. J. Am. Coll. Cardiol. 2018;71:752–763. doi: 10.1016/j.jacc.2017.12.010. PubMed DOI

Dafni U. Landmark analysis at the 25-year landmark point. Circ. Cardiovasc. Qual. Outcomes. 2011;4:363–371. doi: 10.1161/CIRCOUTCOMES.110.957951. PubMed DOI

Anderson J.R., Cain K.C., Gelber R.D. Analysis of survival by tumor response. J. Clin. Oncol. 1983;1:710–719. doi: 10.1200/JCO.1983.1.11.710. PubMed DOI

Jansa P., Ambrož D., Kuhn M., Dytrych V., Aschermann M., Černý V., Gressin V., Heller S., Kunstýř J., Širanec M., et al. Epidemiology of chronic thromboembolic pulmonary hypertension (CTEPH) in the Czech Republic. Pulm. Circ. 2022;12:e12038. doi: 10.1002/pul2.12038. PubMed DOI PMC

IHIS CR. Institute of Health Information and Statistics. [(accessed on 19 July 2022)]. Available online: https://www.uzis.cz/index-en.php.

Pocock S.J., Clayton T.C., Altman D.G. Survival plots of time-to-event outcomes in clinical trials: Good practice and pitfalls. Lancet. 2002;359:1686–1689. doi: 10.1016/S0140-6736(02)08594-X. PubMed DOI

Hoeper M.M., Kramer T., Pan Z., Eichstaedt C.A., Spiesshoefer J., Benjamin N., Olsson K.M., Meyer K., Vizza C.D., Vonk-Noordegraaf A., et al. Mortality in pulmonary arterial hypertension: Prediction by the 2015 European pulmonary hypertension guidelines risk stratification model. Eur. Respir. J. 2017;50:1700740. doi: 10.1183/13993003.00740-2017. PubMed DOI

Mathai S.C., Mathew S. Breathing (and coding?) a bit easier: Changes to international classification of disease coding for pulmonary hypertension. Chest. 2018;154:207–218. doi: 10.1016/j.chest.2018.04.004. PubMed DOI

Peacock A., Keogh A., Humbert M. Endpoints in pulmonary arterial hypertension: The role of clinical worsening. Curr. Opin. Pulm. Med. 2010;16((Suppl. S1)):S1–S9. doi: 10.1097/01.mcp.0000370205.22885.98. PubMed DOI

Ghofrani H.A., D’Armini A.M., Grimminger F., Hoeper M.M., Jansa P., Kim N.H., Mayer E., Simonneau G., Wilkins M.R., Fritsch A., et al. Riociguat for the treatment of chronic thromboembolic pulmonary hypertension. N. Engl. J. Med. 2013;369:319–329. doi: 10.1056/NEJMoa1209657. PubMed DOI

Jaïs X., D’Armini A.M., Jansa P., Torbicki A., Delcroix M., Ghofrani H.A., Hoeper M.M., Lang I.M., Mayer E., Pepke-Zaba J., et al. Bosentan for treatment of inoperable chronic thromboembolic pulmonary hypertension: BENEFiT (Bosentan Effects in iNopErable Forms of chronIc Thromboembolic pulmonary hypertension), a randomized, placebo-controlled trial. J. Am. Coll. Cardiol. 2008;52:2127–2134. doi: 10.1016/j.jacc.2008.08.059. PubMed DOI

Sadushi-Kolici R., Jansa P., Kopec G., Torbicki A., Skoro-Sajer N., Campean I.-A., Halank M., Simkova I., Karlocai K., Steringer-Mascherbauer R., et al. Subcutaneous treprostinil for the treatment of severe non-operable chronic thromboembolic pulmonary hypertension (CTREPH): A double-blind, phase 3, randomised controlled trial. Lancet Respir. Med. 2019;7:239–248. doi: 10.1016/S2213-2600(18)30367-9. PubMed DOI

Sitbon O., Channick R., Chin K.M., Frey A., Gaine S., Galiè N., Ghofrani H.-A., Hoeper M.M., Lang I.M., Preiss R., et al. Selexipag for the treatment of pulmonary arterial hypertension. N. Engl. J. Med. 2015;373:2522–2533. doi: 10.1056/NEJMoa1503184. PubMed DOI

Ghofrani H.-A., Simonneau G., D’Armini A.M., Fedullo P., Howard L.S., Jaïs X., Jenkins D.P., Jing Z.-C., Madani M.M., Martin N., et al. Macitentan for the treatment of inoperable chronic thromboembolic pulmonary hypertension (MERIT-1): Results from the multicentre, phase 2, randomised, double-blind, placebo-controlled study. Lancet Respir. Med. 2017;5:785–794. doi: 10.1016/S2213-2600(17)30305-3. PubMed DOI

CT.gov NCT04271475. A Study to Evaluate Efficacy and Safety of Macitentan 75 mg in Inoperable or Persistent/Recurrent Chronic Thromboembolic Pulmonary Hypertension (MACiTEPH) [(accessed on 19 July 2022)]; Available online: https://clinicaltrials.gov/ct2/show/NCT04271475.

Burger C.D., Long P.K., Shah M.R., McGoon M.D., Miller D.P., Romero A.J., Benton W.W., Safford R.E. Characterization of first-time hospitalizations in patients with newly diagnosed pulmonary arterial hypertension in the REVEAL registry. Chest. 2014;146:1263–1273. doi: 10.1378/chest.14-0193. PubMed DOI PMC

Balloon pulmonary angioplasty for chronic thromboembolic pulmonary hypertension: a clinical consensus statement of the ESC working group on pulmonary circulation and right ventricular function

Correction: Jansa et al. Hospitalisation Is Prognostic of Survival in Chronic Thromboembolic Pulmonary Hypertension. J. Clin. Med. 2022, 11, 6189